If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
|Videos|May 20, 2021
Gaining Loyalty from New Customers For Opportunities and Better Results
Simko discussed how to retain new patients to continue to bring in new opportunities and better results for pharmacies everywhere.
Advertisement
Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about her presentation "Elevated Patients Experiences: Lengthen the Patient Lifecycle to Increase Revenue."
Simko discussed how to retain new patients to continue to bring in new opportunities and better results for pharmacies everywhere.
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
2
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
3
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5